drugset / Trial / NCT02550106
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
Non-randomizedSingle-groupSingle-blindTreatment
Summary
Evaluate the proportion of patients with an urticaria control test \[UCT\] score of greater than or equal to 12 at Week 12.
Timeline
- Start
- 2015-04-22
- Primary completion
- 2016-01-11
- Completion
- 2016-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | 300 mg | Subcutaneous |